WHOLOMICS

Innovative Multi-Cancer Early Detection
through Advanced Multiomics & AI

LSI PRESENTATION:

“THE FUTURE OF EARLY CANCER DIAGNOSTICS”

Thursday, March 20th 2025, 10 AM Track 3

Patrick Strasser, CEO & Co-Founder of Wholomics on their novel liquid biopsy approach for early cancer detection

Proven highly accurate across 10+ cancer types.

Wholomics´ break through technology will change the game in some of the toughest to treat cancers by finding and starting treatment where it matters most: EARLY.

THE BIG PROBLEM:
LATE STAGE DIAGNOSIS

Late diagnosis remains one of the most critical challenges in healthcare, leading to significantly lower survival rates and skyrocketing treatment costs.

Most cancers are not detected until they have advanced beyond the point of curability, leaving patients with limited treatment options and poor outcomes.

Table 1: 5-year survival rates of different types of cancer when diagnosed in the local (early) stage or in the distant stage (late stage).
*[5-year survival rate (%)]

This delay is often due to the lack of accessible, non-invasive screening tools capable of identifying cancer in its earliest stages.

Wholomics is addressing this challenging task by providing a novel blood based early detection test aiming on reducing the burden on healthcare systems while saving patient lives.

Revolutionizing Cancer Screening for Better Outcomes

Wholomics is revolutionizing early cancer detection with a state-of-the-art metabolomics-based Multi-Cancer Early Detection (MCED) test. We combine powerful AI algorithms with metabolite profiling to deliver early, accurate, and actionable cancer risk stratification.

Proven Technology

Validated across multiple cohorts, achieving state of the art early stage sensitivity.

Market Opportunity

Targeting high-impact solid tumors, our solution meets a critical and growing global demand for early cancer diagnostics.

Scalable Technology

Our NMR-based screening method scales seamlessly, enabling processing of thousands of samples with robust accuracy.

Clinical Validation

Developed and validated in multi-centric clinical cohorts, spanning multiple EU countries and soon the US.

Join Us in Transforming Cancer Detection

We're actively seeking visionary investors to support our journey toward a transformative change in cancer care.


With CLIA lab setup, validation studies and market entry coming up, Wholomics is in an critical phase of acceleration, providing a huge opportunity to change the world and benefit financially.